Daniel Vilarim AraÃojo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5752286/publications.pdf

Version: 2024-02-01

24 papers 490 citations

1039406 9 h-index 752256 20 g-index

24 all docs

24 docs citations

times ranked

24

602 citing authors

#	Article	IF	Citations
1	Beyond immune checkpoint blockade: emerging immunological strategies. Nature Reviews Drug Discovery, 2021, 20, 899-919.	21.5	208
2	Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5â€fluorouracil resistance in metastatic colorectal cancer patients. International Journal of Cancer, 2015, 137, 1397-1405.	2.3	52
3	MRP1 expression in CTCs confers resistance to irinotecanâ€based chemotherapy in metastatic colorectal cancer. International Journal of Cancer, 2016, 139, 890-898.	2.3	45
4	Designing circulating tumor DNA-based interventional clinical trials in oncology. Genome Medicine, 2019, 11, 22.	3.6	24
5	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study., 2021, 9, e003476.		20
6	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. Medical Oncology, $2019, 36, 8$.	1.2	16
7	Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. European Journal of Cancer, 2021, 158, 85-98.	1.3	16
8	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. Cancer Treatment Reviews, 2021, 92, 102125.	3.4	15
9	Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Current Oncology, 2021, 28, 2173-2179.	0.9	14
10	Early circulating tumor DNA (ctDNA) kinetics using a tumor-naÃ-ve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials Journal of Clinical Oncology, 2022, 40, 2546-2546.	0.8	13
11	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. JNCI Cancer Spectrum, 2021, 5, pkaa122.	1.4	12
12	Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV. JAMA Network Open, 2019, 2, e1914816.	2.8	11
13	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. Journal of Geriatric Oncology, 2021, 12, 820-826.	0.5	10
14	The Day After COVID-19—Time to Rethink Oncology Clinical Research. JAMA Oncology, 2021, 7, 23.	3.4	6
15	Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model. Ecancermedicalscience, 2019, 13, 967.	0.6	6
16	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. Cancers, 2022, 14, 89.	1.7	5
17	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Targeted Oncology, 2022, 17, 253-270.	1.7	5
18	Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma Journal of Clinical Oncology, 2022, 40, 9579-9579.	0.8	5

#	Article	IF	CITATIONS
19	Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Cancers, 2021, 13, 3640.	1.7	4
20	Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil. Ecancermedicalscience, 2021, 15, 1269.	0.6	1
21	Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma. Journal of Investigative Dermatology, 2021, 141, 2470-2479.	0.3	1
22	Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer Journal of Clinical Oncology, 2022, 40, e24120-e24120.	0.8	1
23	Is there a role for surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC)?. Journal of Clinical Oncology, 2022, 40, 5092-5092.	0.8	O
24	Patient-centered trials in oncology: Time for a change. Med, 2022, 3, 445-449.	2.2	0